A Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP)
← catalyst calendarNCT06338995 · readout ≤ 285 d
Sponsored by Eli Lilly and Company (industry) · LLY — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
510estimated
Sites
202
Countries
Argentina, Belgium, Bulgaria +17
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-04-29 | actual | When the study began enrolling |
| Primary completion | May 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Mar 2028 | estimated | The whole study's end, after follow-up |
| First posted | 2024-04-01 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-06 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
Interventions
- Drug: LY3650150
- Drug: Placebo
- Drug: Standard therapy for INCS
Primary outcomes
what the primary-completion date above is the date OFMean Change From Baseline (CFBL) in Participant Reported Nasal Congestion Score (NCS) Severity
measured Baseline, Week 24
Mean CFBL in Endoscopic Nasal Polyp Score (NPS)
measured Baseline, Week 24
Permalink · LLY's whole pipeline · Catalyst calendar · Every registered study · What changed